Concurrent Investment Advisors LLC Raises Stock Position in AngioDynamics, Inc. (NASDAQ:ANGO)

Concurrent Investment Advisors LLC raised its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 152.2% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 29,503 shares of the medical instruments supplier’s stock after buying an additional 17,803 shares during the period. Concurrent Investment Advisors LLC owned about 0.07% of AngioDynamics worth $178,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of ANGO. Quest Partners LLC purchased a new stake in AngioDynamics during the fourth quarter valued at $69,000. RPO LLC purchased a new stake in shares of AngioDynamics during the 4th quarter valued at about $83,000. State Board of Administration of Florida Retirement System lifted its stake in shares of AngioDynamics by 44.1% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 15,627 shares of the medical instruments supplier’s stock worth $92,000 after purchasing an additional 4,780 shares during the period. Bayesian Capital Management LP purchased a new position in shares of AngioDynamics in the first quarter worth approximately $106,000. Finally, Price T Rowe Associates Inc. MD grew its position in AngioDynamics by 9.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 33,772 shares of the medical instruments supplier’s stock valued at $199,000 after buying an additional 2,821 shares during the period. 89.43% of the stock is owned by institutional investors.

Analyst Ratings Changes

ANGO has been the topic of several recent research reports. Canaccord Genuity Group decreased their price target on shares of AngioDynamics from $18.00 to $13.00 and set a “buy” rating on the stock in a research report on Wednesday, July 17th. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 target price on shares of AngioDynamics in a report on Wednesday, July 17th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, AngioDynamics has a consensus rating of “Moderate Buy” and a consensus price target of $12.25.

AngioDynamics Trading Up 0.1 %

NASDAQ ANGO opened at $7.33 on Thursday. The stock has a market cap of $293.60 million, a price-to-earnings ratio of -1.52 and a beta of 0.66. AngioDynamics, Inc. has a 12 month low of $5.26 and a 12 month high of $8.25. The company’s 50 day moving average is $7.01 and its two-hundred day moving average is $6.36.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Tuesday, July 16th. The medical instruments supplier reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.11. The company had revenue of $71.00 million for the quarter, compared to analysts’ expectations of $70.86 million. AngioDynamics had a negative net margin of 61.55% and a negative return on equity of 4.91%. AngioDynamics’s revenue for the quarter was down 22.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.02 EPS. Sell-side analysts forecast that AngioDynamics, Inc. will post -0.41 EPS for the current year.

About AngioDynamics

AngioDynamics, Inc provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease.